A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab▼ in patients with primary and secondary progressive multiple sclerosis: Year 2 interim analysis
This poster reports the Year 2 safety and effectiveness outcomes from the CONSONANCE study (patients with SPMS and PPMS treated with ocrelizumab▼).
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.